Stockreport

Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 [Seeking Alpha]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF PRAX's relutrigine and ulixacaltamide both achieved pivotal clinical milestones, with two NDA submissions likely in 2025 and potential blockbuster revenue projections. [Read more]